{"id":43510,"date":"2022-08-03T07:25:09","date_gmt":"2022-08-03T07:25:09","guid":{"rendered":"https:\/\/i-base.info\/htb\/?p=43510"},"modified":"2022-09-12T07:17:37","modified_gmt":"2022-09-12T07:17:37","slug":"ema-approves-imvanex-vaccine-against-monkeypox-in-eu","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/43510","title":{"rendered":"EMA approves Imvanex vaccine against monkeypox in EU"},"content":{"rendered":"
\n

Simon Collins, HIV i-Base<\/strong><\/p>\n<\/div>\n

\n

\"\"On 22 July 2022, the EU committee responsible for reviewing medicines (CHMP) recommended extending the indication for Imvanex to include monkeypox (MPX). [1]<\/span><\/strong><\/p>\n<\/div>\n

\n

Imvanex was approved in the EU as a smallpox vaccine in 2013. [2]<\/span><\/p>\n<\/div>\n

\n

Imvanex was approved in the US both for smallpox and monkeypox in 2019 where it is marketed as JYYNEOS. [3]<\/span><\/p>\n<\/div>\n

\n

This included additional information from some studies. [4]<\/span><\/p>\n<\/div>\n

\n

\u00a0References<\/span><\/p>\n<\/div>\n

\n
    \n
  1. EMA News. EMA recommends approval of Imvanex for the prevention of monkeypox disease. (22 July 2022).
    \n<\/span>https:\/\/www.ema.europa.eu\/en\/news\/ema-recommends-approval-imvanex-prevention-monkeypox-disease<\/a><\/li>\n
  2. EMA. Imvanex product information. (2013).
    \n    https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/imvanex<\/a><\/li>\n
  3. US FDA, FDA approves first live, non-replicating vaccine to prevent smallpox and monkeypox. (24 September 2019)
    \n    https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-live-non-replicating-vaccine-prevent-smallpox-and-monkeypox<\/a><\/li>\n
  4. US Office of Vaccines Research and Review (OVRR). Review memorandum for Jynneos vaccine. (2018)
    \n    https:\/\/www.fda.gov\/media\/131870\/download<\/a><\/li>\n<\/ol>\n<\/div>\n
    \n

    \u00a0This report was first published on 27 July 2022.<\/em><\/span><\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"

    Simon Collins, HIV i-Base On 22 July 2022, the EU committee responsible for reviewing medicines (CHMP) recommended extending the indication for Imvanex to include monkeypox (MPX). [1] Imvanex was approved in the EU as a smallpox vaccine in 2013. [2] …<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[323,31],"tags":[],"class_list":["post-43510","post","type-post","status-publish","format-standard","hentry","category-mpox","category-opportunistic-infections-coinfections-and-complications"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/43510","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=43510"}],"version-history":[{"count":1,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/43510\/revisions"}],"predecessor-version":[{"id":44015,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/43510\/revisions\/44015"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=43510"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=43510"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=43510"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}